XAIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Beyond Air Inc (XAIR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently oversold based on RSI, but the technical indicators, financial performance, and lack of positive catalysts suggest caution. The investment scenario does not align with the user's impatience and unwillingness to wait for optimal entry points.
The stock is in a bearish trend with SMA_200 > SMA_20 > SMA_5. The MACD histogram is negative (-0.0146) and contracting, indicating weak momentum. RSI_6 is at 19.693, signaling oversold conditions. Key support is at 0.801, and resistance is at 0.905. The stock is trading below its pivot level, reflecting bearish sentiment.
Analysts believe the potential commercialization of the second-generation LungFit PH system could drive high revenue growth and profitability in the long term.
No recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q3 2026, revenue increased by 104.66% YoY to $2,194,000. However, net income dropped to -$7,336,000 (-43.71% YoY), EPS fell to -0.85 (-71.28% YoY), and gross margin declined to 13.67 (-168.15% YoY). The company's profitability metrics are deteriorating despite revenue growth.
Analysts have a mixed view. Rodman & Renshaw initiated coverage with a Buy rating and a $5 price target. However, JonesResearch lowered the price target from $6 to $2, citing delays in FDA approval and reduced sales estimates. Analysts are optimistic about the long-term potential of the LungFit PH system but cautious about near-term performance.
